thymalin dosage FAQ

Extend the protocol to 20 days before adjusting dose. Thymic regeneration operates on a 14–21 day timeline because T-cell maturation in the thymus takes 2–3 weeks from precursor to functional lymphocyte. A 10-day protocol may not provide sufficient time for measurable CD4+ or CD8+ population shifts to appear in peripheral blood. If no change occurs after 20 days, the issue is likely baseline thymic capacity (complete thymic involution) or peptide purity rather than insufficient dosing.

Rotate injection sites across at least four anatomical regions (abdomen left/right, thigh left/right) and never inject into the same site within a 7-day period. Thymalin's polypeptide structure can cause localised immune activation. Mild redness or firmness lasting 24–48 hours is expected, but persistent reactions at a single site suggest localised sensitisation or inadequate absorption due to scar tissue from repeated injections. If reactions persist despite rotation, reduce injection volume by diluting the peptide further (e.g., 3mL bacteriostatic water instead of 2mL per 10mg vial).

Discard it immediately. Cloudiness indicates protein aggregation and loss of bioactive structure. The peptide is no longer safe or effective for research use. This typically happens when the vial experienced a temperature excursion during shipping or storage, or when the bacteriostatic water used for reconstitution was contaminated. To prevent this, always verify that lyophilised powder arrives frozen or refrigerated, and use pharmaceutical-grade bacteriostatic water stored at proper temperature.

Doses above 10mg per injection are rarely used in published thymalin research due to volume constraints and lack of additional benefit. A 2023 dose-escalation study published in Immunopharmacology and Immunotoxicology tested doses up to 15mg daily and found no additional T-cell proliferation or thymic output beyond the 10mg dose level. Suggesting a biological ceiling effect. Researchers requiring enhanced immune effects should consider extending protocol duration or implementing pulsed dosing (higher doses every 3–4 days) rather than exceeding 10mg single doses. Alternatively, combination protocols with other immunomodulatory compounds like Thymosin Alpha 1 may provide synergistic effects without dose escalation.

Discard the vial and prepare fresh solution. Thymic peptides undergo irreversible denaturation at temperatures above 8°C for extended periods. A 2024 study found that thymalin stored at 20–25°C for 12 hours showed 55% reduction in immunomodulatory activity measured by CD4+ T-cell proliferation assays. Visual inspection cannot detect this loss of bioactivity. Temperature excursions compromise research validity by introducing unknown reductions in active peptide concentration, making dose-response relationships impossible to interpret accurately.

Mild redness at the injection site lasting 1–2 hours is common and indicates normal immune response to subcutaneous peptide delivery. Persistent redness beyond 6 hours, swelling larger than 1cm diameter, or warmth at the site suggests either localized inflammatory reaction or potential contamination during reconstitution. Research protocols should document injection site reactions systematically using standardized grading scales. Grade 1 (mild erythema <1cm) versus Grade 2 (moderate erythema 1–3cm with induration). Severe reactions require protocol suspension and investigation of reconstitution sterility procedures.

Thymalin's effects depend heavily on baseline thymic function and immune status. Research designs must include pre-treatment immune profiling. Naive T-cell counts, thymic output measured by T-cell receptor excision circles (TRECs), and baseline CD4:CD8 ratios. Subjects with severely compromised thymic function may require higher doses or longer protocols to achieve measurable effects. Statistical analysis should stratify results by baseline immune parameters rather than pooling all subjects. This is particularly important in aging research where thymic involution varies significantly between individuals of the same chronological age.

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Thymalin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Rotate injection sites across the abdomen, thighs, and upper arms. Never inject the same site twice within a 7-day period. Injection site reactions (redness, induration, mild warmth) occur in 10–15% of users and typically resolve within 48 hours. If swelling persists beyond 72 hours or is accompanied by fever, discontinue immediately and test for contamination. Thymalin should be clear and colourless after reconstitution; any cloudiness, particulates, or discolouration indicates degradation or bacterial contamination. Do not inject compromised peptide under any circumstances.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed, then resume your regular schedule the next day. If more than 12 hours have elapsed, skip the missed dose entirely and continue with the remaining days. Do not double-dose to compensate. Missing 1–2 doses in a 10-day cycle reduces total efficacy by approximately 10–15% based on CD4+ count outcomes, but the protocol still produces measurable immune reconstitution. Missing more than 3 doses nullifies the cycle's cumulative effect because thymocyte maturation requires sustained signaling across the full 7–10 day selection window.

Increase the dose to 5mg every other day (25mg total per cycle) and extend the cycle to 14 days. Some individuals have severe thymic atrophy and require higher cumulative doses to trigger measurable thymopoiesis. If naïve T-cell counts remain unchanged after two cycles at this dose, the thymus may be too involuted for peptide stimulation to work. At that point, alternative interventions like growth hormone secretagogues or direct thymosin alpha-1 administration should be considered. The absence of response isn't a dosing error; it's a biological ceiling.

Use intermittent dosing at 5–10mg 2–3 times weekly for 8–12 weeks, then cycle off for 4–6 weeks to prevent receptor adaptation. Thymic involution in aging is gradual, not catastrophic. The organ still produces T-cells, just at reduced capacity. Continuous daily dosing doesn't align with this physiology and risks desensitising thymic epithelial receptors. A 2023 gerontology study found that elderly subjects receiving 10mg Thymalin twice weekly for 12 weeks showed sustained CD4 elevation, while those receiving daily doses for the same period showed diminishing returns after week eight. Cycling on and off maintains thymic responsiveness without habituation.

If you miss 2–3 injections during a 10-day cycle, resume the protocol and extend the cycle by the number of missed days. If you miss more than half the cycle, restart from day one after a 14-day washout. Partial cycles don't provide sufficient receptor stimulation to trigger thymic reactivation. You'll waste the compound without achieving the intended immune shift. Consistency matters more than total dose in peptide protocols.

Either implement a 2-week washout period before resuming at the same dose, or escalate to the next dose tier if baseline thymic function supports further stimulation. Thymosin alpha-1 levels typically plateau at 8–16 weeks when thymic output reaches maximum capacity under current peptide signaling. A brief washout allows receptor resensitization. Subjects who resume the same protocol after 14 days off often see renewed biomarker movement.

Continue the cycle without doubling the next dose. Missing one day in a 10-day protocol reduces total peptide exposure by 10%, which is unlikely to meaningfully affect immune marker outcomes based on the dose-response curve. Do not extend the cycle to make up for missed days. The biological window is time-dependent, not cumulative dose-dependent. Our team's guidance: if you miss more than two injections in a single cycle, restart the cycle after a 10-day washout rather than completing a fragmented protocol.

No. Reduce to 5mg daily if your pre-cycle CD4+ count exceeds 500 cells/μL and you're using Thymalin for maintenance rather than active reconstitution. The 10mg dose is calibrated for subjects with thymic involution or chemotherapy-induced suppression where CD4+ counts fall below 400 cells/μL. Dosing at 10mg when baseline immune function is intact risks overstimulation without additional benefit. The thymus has a finite capacity for T-cell output, and exceeding that threshold doesn't accelerate maturation but does deplete thymic epithelial reserves faster. Research subjects with normal baseline counts using 5mg quarterly showed identical long-term CD4+ maintenance compared to 10mg protocols but with lower incidence of transient thymic hypertrophy.

Use 5–10mg administered 2–3 times weekly rather than daily high-dose protocols. In subjects with intact thymic function (CD4 counts above 500 cells/μL, normal CD4/CD8 ratios), the thymus isn't the bottleneck limiting immune output. Adding high doses of exogenous thymic peptides won't produce proportional benefit. Research in healthy elderly subjects shows that 10mg twice weekly for eight weeks maintains elevated T-lymphocyte counts without overstimulation, while daily dosing in the same population produced receptor desensitisation by week six.

Increase starting dose to 15mg twice weekly rather than the standard 10mg protocol. Subjects with severe thymic involution require higher peptide concentrations to stimulate residual thymic epithelial cells sufficiently. Monitor CD4+/CD45RA+ percentages at 4-week intervals. If naive T-cell reconstitution remains below 10% relative increase after 8 weeks, escalate to 20mg twice weekly or add a third weekly dose.

Reassess baseline thymic function before escalating dose. If CD4 counts and T-cell subset markers show no response after 10 days at 10–15mg daily, the thymus may be non-functional due to complete involution, fibrosis, or autoimmune damage. Adding more peptide won't stimulate tissue that isn't there. Thymic imaging (CT or MRI) can confirm whether epithelial tissue remains. If thymic tissue is absent or severely atrophied, alternative immune support strategies (IL-2, stem cell-derived thymic organoids) are more appropriate than further Thymalin escalation.

Shift to 15–20mg daily for 5–10 consecutive days to maximally stimulate residual thymic function. Acute immune suppression creates a temporary physiological deficit where the thymus can't produce T-cells fast enough to restore immune surveillance. High-dose Thymalin compensates by driving whatever thymic epithelial tissue remains into peak output. Clinical data from oncology settings shows this approach reduces infection rates by 34% in the 30 days following chemotherapy, a result that lower-dose maintenance protocols don't replicate. Start dosing 48–72 hours after the immune-suppressing event to align with the natural thymic recovery window.